Market Research Logo

4SC AG - Product Pipeline Review - 2016

4SC AG - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘4SC AG - Product Pipeline Review - 2016’, provides an overview of the 4SC AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by 4SC AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of 4SC AG
  • The report provides overview of 4SC AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses 4SC AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features 4SC AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate 4SC AG’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for 4SC AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 4SC AG’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


4SC AG Snapshot
4SC AG Overview
Key Information
Key Facts
4SC AG - Research and Development Overview
Key Therapeutic Areas
4SC AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
4SC AG - Pipeline Products Glance
4SC AG - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
4SC AG - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
4SC AG - Drug Profiles
resminostat
Product Description
Mechanism of Action
R&D Progress
vidofludimus
Product Description
Mechanism of Action
R&D Progress
4SC-202
Product Description
Mechanism of Action
R&D Progress
4SC-205
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Malaria
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Neurological Disorders
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Bromodomain for Cancer
Product Description
Mechanism of Action
R&D Progress
4SC AG - Pipeline Analysis
4SC AG - Pipeline Products by Target
4SC AG - Pipeline Products by Route of Administration
4SC AG - Pipeline Products by Molecule Type
4SC AG - Pipeline Products by Mechanism of Action
4SC AG - Recent Pipeline Updates
4SC AG - Dormant Projects
4SC AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
4SC-203
4SC-207
resminostat
4SC AG - Company Statement
4SC AG - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
4SC AG, Key Information
4SC AG, Key Facts
4SC AG - Pipeline by Indication, 2016
4SC AG - Pipeline by Stage of Development, 2016
4SC AG - Monotherapy Products in Pipeline, 2016
4SC AG - Partnered Products in Pipeline, 2016
4SC AG - Partnered Products/ Combination Treatment Modalities, 2016
4SC AG - Phase II, 2016
4SC AG - Phase I, 2016
4SC AG - Preclinical, 2016
4SC AG - Discovery, 2016
4SC AG - Pipeline by Target, 2016
4SC AG - Pipeline by Route of Administration, 2016
4SC AG - Pipeline by Molecule Type, 2016
4SC AG - Pipeline Products by Mechanism of Action, 2016
4SC AG - Recent Pipeline Updates, 2016
4SC AG - Dormant Developmental Projects,2016
4SC AG - Discontinued Pipeline Products, 2016
ist of Figures
4SC AG - Pipeline by Top 10 Indication, 2016
4SC AG - Pipeline by Stage of Development, 2016
4SC AG - Monotherapy Products in Pipeline, 2016
4SC AG - Partnered Products in Pipeline, 2016
4SC AG - Pipeline by Target, 2016
4SC AG - Pipeline by Route of Administration, 2016
4SC AG - Pipeline by Molecule Type, 2016
4SC AG - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report